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Abstract
Lyophilisomes are a novel class of biodegradable proteinaceous nano/micrometer capsules with potential use as drug
delivery carrier. Cell-penetrating peptides (CPPs) including the TAT peptide have been successfully implemented for
intracellular delivery of a broad variety of cargos including various nanoparticulate pharmaceutical carriers. In the present
study, lyophilisomes were modified using CPPs in order to achieve enhanced cellular uptake. Lyophilisomes were prepared
by a freezing, annealing, and lyophilization method and a cystein-elongated TAT peptide was conjugated to the
lyophilisomes using a heterobifunctional linker. Fluorescent-activated cell sorting (FACS) was utilized to acquire a
lyophilisome population with a particle diameter smaller than 1000 nm. Cultured HeLa, OVCAR-3, Caco-2 and SKOV-3 cells
were exposed to unmodified lyophilisomes and TAT-conjugated lyophilisomes and examined with FACS. HeLa cells were
investigated in more detail using a trypan blue quenching assay, confocal microscopy, and transmission electron
microscopy. TAT-conjugation strongly increased binding and cellular uptake of lyophilisomes in a time-dependent manner
in vitro, as assessed by FACS. These results were confirmed by confocal microscopy. Transmission electron microscopy
indicated rapid cellular uptake of TAT-conjugated lyophilisomes via phagocytosis and/or macropinocytosis. In conclusion,
TAT-peptides conjugated to albumin-based lyophilisomes are able to enhance cellular uptake of lyophilisomes in HeLa cells.
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Introduction
An innovative strategy in cancer therapy utilizes drug delivery
carriers to increase the therapeutic effect of anti-tumor drugs. The
role of drug delivery carriers in this context is to improve
pharmacokinetics and dynamics by protecting the drug from
degradation [1–3]. Contemporary drug delivery systems include
nanoparticulate systems loaded with anti-tumor drug and conju-
gates directly coupled to the drug. The unique property of
nanoparticle carriers is their ability to encapsulate and deliver a
high dose of anti-tumor drugs, including poorly soluble drugs, and
to exploit the enhanced permeability and retention (EPR) effect for
tumor targeting [4]. Because of these favorable characteristics,
there has been intense interest in the development of nanoparti-
culate drug delivery systems.
Nanoparticles currently investigated for cancer therapeutic
applications include liposomes, polymersomes, dendrimers, mi-
celles, carbon nanotubes, nanoconjugates and (protein-based)
nanospheres or capsules [5–7]. Among the available potential
drug carrier systems, protein-based nanoparticles are particularly
interesting as they hold certain advantages such as good stability
during storage, non-toxicity, biocompatibility, and biodegradabil-
ity in vivo [8,9]. Recently we showed that lyophilisomes, a novel
class of proteinaceous biodegradable hollow nano/micrometer
capsules, show potential as a drug delivery capsule [10,11].
Lyophilisomes can be prepared from a large variety of water-
soluble macromolecules including proteins (e.g. albumin and
elastin) but also polysaccharides (e.g. heparin). In fact, virtually any
biomolecule can be incorporated into the wall/lumen of the
capsule, resulting in a highly flexible carrier system with multiple
applications. We previously demonstrated that enzymes intro-
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duced in the capsule’s wall and in the lumen are bioactive and able
to convert a substrate [10]. Furthermore, lyophilisomes have been
efficiently loaded with doxorubicin resulting in tumor cell
elimination in vitro [11]. In order to obtain a selective drug
delivery system, lyophilisomes have also been modified with
antibodies, resulting in specific targeting of the cell of interest in
vitro [12]. Due to these properties, lyophilisomes can be deployed
for the design of multifunctional targeting systems.
Lyophilisomes were prepared from albumin. Albumin is an
attractive macromolecular carrier that has been shown to be non-
toxic, non-immunogenic, biodegradable to produce innocuous
degradation products, and easy to purify [13]. It is thus a suitable
candidate for nanoparticle preparation, as demonstrated by FDA-
approved products such as Abraxane [14,15] and Albunex
[16,17].
Since delivery of nanocarriers is generally based on passive
accumulation in pathological tissues, they do not efficiently deliver
their cargo to specific cells. When drug delivery carriers arrive at
the tumor site, they have to cross the plasma membrane in order
to deliver the drug into the cell. The plasma membrane, however,
prevent proteins, peptides, and nanoparticulate drug carriers from
entering the cell in the absence of an active transport mechanism
[18]. Cell-penetrating peptides (CPPs) have been successfully used
to deliver a large variety of cargos to the cell interior including
proteins [19], peptides [20], nucleic acids [21] and pharmaceutical
nanocarriers [22–24]. CPPs are short peptides consisting of up to
30 amino acids that are able to translocate across the cellular
membrane [25]. When CPPs are conjugated to drug delivery
carriers, efficient cellular uptake of the carriers can be achieved
[26]. A representative CPP is the TAT peptide, derived from the
TAT protein (trans-activation transcriptional activator) of the
human immunodeficiency virus type 1 (HIV-1) [27,28]. The TAT
peptide consists of 11 amino acids with the sequence
YGRKKRRQRRR. The abundance of lysine and arginine
residues makes it highly positively charged, important for the
interaction with the plasma membrane. In this study, the TAT
peptide was conjugated to lyophilisomes to investigate whether
CPPs are able to enhance cellular uptake of lyophilisomes.
Materials and Methods
Bovine serum albumin was purchased from PAA Laboratories
(Linz, Austria). FITC-conjugated bovine albumin was purchased
from Sigma Aldrich (Steinheim, Germany). Sulfo-GMBS (sulfo-N-
[c-maleimidobutyryloxy]sulfosuccinimide ester) was purchased
from Pierce Biotechnology (Rockford, IL, USA). Glutaraldehyde
and formaldehyde were obtained from Merck (Darmstadt,
Germany). Cysteine functionalized TAT peptide (C-Ahx-
YGRKKRRQRRR) was purchased from EMC Microcollections
GmbH (Tu¨bingen, Germany), in which Ahx = aminohexanoic
acid linker.
Preparation of lyophilisomes
Lyophilisomes were prepared from albumin as described
previously [11]. Briefly, droplets of a solution of 0.25% (w/v)
bovine serum albumin (BSA) in 0.01 M acetic acid were frozen in
liquid nitrogen (2196uC). The frozen albumin preparation was
incubated at 210 to 220uC for 3 h (annealing step), and
subsequently lyophilized. This procedure results in hollow nano/
micro spheres (‘‘lyophilisomes’’). In order to visualize the
lyophilisomes, FITC-conjugated albumin was added to non-
labeled albumin (1:10) in the starting solution. To obtain stabilized
lyophilisomes, they were vapor crosslinked with glutaraldehyde
and formaldehyde. Generally we prepare 40 ml of a 0.25% BSA
solution, which corresponds to 100 mg albumin (2.5 mg/ml). The
final lyophilisome population was centrifuged three or four times
at low speed (606g; Thermo, Heraeus Fresco 17; Newport
Pagnell, Great Britain) to remove large lyophilisomes and sheet-
like structures, until no pellet was observed. After this procedure,
about 30% of the original weight of lyophilisomes remained.
Lyophilisomes (1 mg/ml) were stored in 0.1% (v/v) Tween-20
(Sigma Aldrich, Steinheim, Germany) in phosphate buffered saline
(PBS-T, pH 7.4).
Conjugation of cell-penetrating peptide to lyophilisomes
A schematic representation of the conjugation reactions is
depicted in figure 1.
Reaction 1. Activation of lyophilisomes. To obtain malei-
mide-activated lyophilisomes, 1 mg lyophilisomes were resus-
pended in 1 ml PBS-T and incubated overnight with 31 ml of
10 mM sulfo-GMBS in PBS-T (pH 8.0) at 4uC on a rotator
(36 rpm, ‘‘Assistant’’ Rotating mixer, Karl Hecht, Sondheim,
Germany), resulting in a 20:1 molar ratio of sulfo-GMBS:albumin.
Excess sulfo-GMBS was removed by centrifugation (5 min,
17,0006g, 4uC) with three washing steps in PBS-T (pH 6.5).
Reaction 2. Conjugation of TAT peptide to lyophilisomes.
For the coupling reaction, 1 ml of 1 mg/ml sulfhydryl-reactive
lyophilisomes in 0.1% PBS-T was centrifuged and conjugated in
1 ml of cysteine functionalized TAT peptide (100 mM; C-Ahx-
YGRKKRRQRRR) in 0.1% PBS-T (pH 6.5). Non-coupled TAT
peptides were removed by centrifugation, using three washing
steps in 0.1% PBS-T (pH 7.4). TAT-conjugated lyophilisomes
were stored at 4uC in the dark.
Sorting of lyophilisomes by fluorescence-activated cell
sorting
Fluorescence-activated cell sorting (FACS) was applied to select
for small lyophilisomes (,1,000 nm) using a Coulter Epics Elite
flow cytometer (BeckmanCoulter, Miami, FL, USA). Only small
FITC-positive lyophilisomes were sorted (for settings, see section
‘‘Lyophilisomes sorted by fluorescence-activated cell sorting’’). To
achieve high sensitivity, gain was set at 20.
Particle size measurements by qNano
The qNano (Izon, Science Ltd., Burnside, New Zealand) was
used to measure particle size distribution of lyophilisomes [11,29].
To ensure a continuous flow of particles, a pore size of 600–
2000 nm was used. Data were analyzed with Izon Control Suite
2.1 software.
Cell culture
HeLa (ACC 57, DSMZ, Braunschweig, Germany) and
OVCAR-3 (#HTB-161, ATCC, LGC Standards GmbH, Wesel,
Germany) cells were cultured in RPMI 1640 GlutaMAX medium
Gibco (Karlsruhe, Germany) supplemented with 10% (v/v) fetal
calf serum (FCS; PAA Laboratories, Pasching, Austria). Caco-2
cells (#HTB-37, ATCC) and SKOV-3 cells (#HTB-77, ATCC)
were cultured in DMEM 1640 GlutaMAX medium Gibco
supplemented with 20% (v/v) and 10% (v/v/) fetal calf serum,
respectively. Cells were cultured in a humidified atmosphere with
5% CO2 at 37uC. Subconfluent cells were dissociated with 0.05%
trypsin (w/v) in 0.02% ethylenediaminetetraacetic acid (EDTA)
(w/v) in PBS (PAA Laboratories) and were maintained as
proliferating cultures.
For FACS, cells were stained with the plasma membrane dye
PKH26 (Sigma Aldrich, Missouri, USA) [30,31]. One million cells
were incubated in 2 mM PKH26 dye in 500 ml buffer (according to
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manufacturer’s protocol) for 5 min. To stop the staining reaction,
500 ml FCS was added and incubated for 5 min. Subsequently,
cells were washed three times with culture medium.
Cellular binding and internalization of lyophilisomes with
and without TAT peptide
To determine whether the TAT peptide can promote the
binding and internalization of lyophilisomes with HeLa, OVCAR-
3, Caco-2 and SKOV-3 cells were seeded in a 24-well plate
(30,000 cells/well in 1 ml medium). Cells were left to adhere
overnight and subsequently incubated for 1 h with unsorted
lyophilisomes with and without TAT peptide conjugated to them
(25 mg/ml). After incubation, cells were washed three times with
PBS to remove unbound lyophilisomes and harvested with
enzyme-free EDTA solution (PAA Laboratories). Finally, cells
were resuspended in 0.2% BSA in PBS and analyzed by FACS
(FACSCalibur Becton Dickinson, Breda, Netherlands). Using the
appropriate positive and negative controls FACS settings were
adjusted. When lyophilisomes did not bind to cells, lyophilisomes
were depicted at a fluorescent signal of 101 or below and cells were
regarded negative. When lyophilisomes did bind to cells, they
showed a fluorescent signal higher than 101. Data were analyzed
by FlowJo software (Version 9.4, Treestar, Ashland, OR, USA).
Internalization studies of lyophilisomes by cells
FACS. In order to discriminate between attached and
internalized lyophilisomes, a FITC quenching trypan blue assay
was used [32–34]. Quenching of FITC signal occurs because
trypan blue absorbs the light emitted by FITC-labeled lyophili-
somes after excitation. The FITC signal of internalized lyophili-
somes however, is not quenched since trypan blue cannot pass the
plasma membrane. The fluorescence remaining after trypan blue
quenching must therefore result from internalized lyophilisomes,
as only extracellular fluorescence of FITC-lyophilisomes is
quenched.
To investigate the cellular uptake of lyophilisomes, PKH26
stained HeLa cells were seeded in a 24-well plate (30,000 cells/
well) and left to adhere overnight. Cells were incubated with
500,000 FACS-sorted lyophilisomes with and without TAT
peptide for 1 and 4 h. After incubation, cells were washed three
times with 0.2% (w/v) BSA in PBS, dissociated with enzyme-free
EDTA dissociation buffer, resuspended in 1 ml culture medium
and transferred to an eppendorf tube. Subsequently, cells were
washed three times with 0.2% BSA-PBS by centrifugation (3 min,
room temperature, 1006g) and incubated with 0.5% (w/v) trypan
blue for 10 min and washed three times with 0.2% BSA-PBS.
Cells were analyzed by FACSCalibur flowcytometry. Data were
analyzed by FlowJo Software.
Confocal microscopy. To visualize cellular uptake of
lyophilisomes, confocal microscopy was performed on living cells.
HeLa cells were seeded in an 8-well microscopy chamber (Nunc;
30,000 cells/well) and left to adhere overnight. Cells were
incubated with sorted lyophilisomes with and without TAT
peptide using 0.8 and 3.5 million lyophilisomes in 200 ml per
sample for 4 h in RPMI medium containing 10% FCS at 37uC. As
a control, medium without lyophilisomes was used. After
incubation, cells were washed three times, incubated for 5 min
with CellMask Orange (5 mg/ml) to visualize the plasma
membranes and then washed again, all with the same medium.
Cells were kept at 37uC on a temperature controlled microscope
stage and living cells were imaged immediately with a Leica SP5
confocal microscope (Leica Microsystems, Mannheim, Germany).
FITC was excited at 488 nm and emission was collected between
500–550 nm. CellMask orange was excited at 561 nm and
emission was collected between 570–650 nm. Images were
recorded sequentially using Leica Application Suite Software
(Advanced Fluorescence Lite, 2.3.0. build 5131).
Transmission electron microscopy. Cells incubated with
lyophilisomes with and without TAT peptide as described in the
Materials and Methods section ‘‘FACS’’ were embedded in 1.5%
(w/v) agarose, fixed in 2% (v/v) glutaraldehyde in 0.1 M
phosphate buffer (pH 7.4), post-fixed with 1% (w/v) osmium
tetroxide, dehydrated in an ascending series of ethanol, and
embedded in Epon 812. Ultrathin sections (60 nm) were cut and
picked up on Formvar-coated grids, post-stained with lead citrate
and uranyl acetate, and examined with a JEOL 1010 transmission
electron microscope (Tokyo, Japan).
Statistical Analysis
Data are presented as mean with standard deviation. Data of
Results section ‘‘Cellular binding and internalization of lyophili-
somes with and without TAT peptide’’ were analyzed using two-
tailed Student’s t-tests. Data of Results section ‘‘Trypan blue assay
and FACS’’ were analyzed using two-way Anova Bonferroni post-
hoc tests. All statistical analyses were performed in Graphpad
Figure 1. Schematic illustration of the conjugation of the cell-penetrating peptide (CPP) TAT to lyophilisomes. (1) Primary amine
groups of lyophilisomes react with Sulfo-GMBS introducing reactive maleimide groups. (2) CPPs (cysteine-functionalized TAT-peptides; C-Ahx-
YGRKKRRQRRR) are conjugated to maleimide-conjugated lyophilisomes, resulting in stable CPP-conjugated lyophilisomes. Sulfo-GMBS = sulfo-N-[c-
maleimidobutyryloxy]sulfo succinimide ester; Ahx = aminohexanoic acid; TAT = trans-activating transcriptional activator.
doi:10.1371/journal.pone.0110813.g001
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Prism 5.0 (Graphpad, San Diego, CA, USA). P values,0.05 were
considered significant.
Results
Conjugation of TAT peptide to lyophilisomes
To probe the possibility of using CPP for enhanced intracellular
delivery, lyophilisomes were modified with a cysteine-functiona-
lized TAT peptide using the heterobifunctional linker sulfo-GMBS
(Fig. 1). The succinimidyl ester functionality is conjugated to
primary amine groups on the lyophilisome while the maleimide
functionality is used for conjugation to the free thiol of the cysteine
residue coupled to the TAT peptide.
Cellular binding and internalization of lyophilisomes with
and without TAT peptide
To address the presence of the TAT peptide on TAT-
conjugated lyophilisomes, unmodified lyophilisomes and TAT-
conjugated lyophilisomes were administered to HeLa, OVCAR-3,
Caco-2 and OVCAR-3 cells. Using standard FACS as a functional
assay, it is not possible to discriminate between cellular attachment
and internalization. Instead, the total of cell binding and
internalization is measured (Fig. 2). For HeLa cells, TAT-
conjugated lyophilisomes showed an about 8-fold increase in
lyophilisome-positive cells compared to lyophilisomes without the
TAT peptide (8663% and 1264% lyophilisome-positive cells for
TAT-conjugated and unmodified lyophilisomes, respectively.
OVCAR-3 and Caco-2 cells showed about a 5-fold increase in
lyophilisome-positive cells compared to lyophilisomes without the
TAT peptide (lyophilisome-positive cells: 9763% and 1963% for
OVCAR-3; 8763% and 1668% for Caco-2) for TAT-conjugated
and unmodified lyophilisomes, respectively. SKOV-3 cells gave a
high background value when incubated with lyophilisomes
without TAT (67620%), but still showed a 1.6 fold statistically
significant increase with the presence of TAT peptide (95610%).
Lyophilisomes sorted by fluorescence-activated cell
sorting
When using lyophilisomes for tumor targeting, lyophilisomal
size is an important parameter. The initial lyophilisome popula-
tion included sizes up to 2.8 mm (Fig. 3a). To obtain a more
monodisperse capsule population, lyophilisomes were sorted by
FACS. Lyophilisomes were separated based on forward scatter
and FITC fluorescence (FL1 channel; Fig. 3c). To verify the
procedure, a rerun of sorted lyophilisomes was performed
(Fig. 3d). Using this methodology, larger lyophilisomes as well as
sheet-like structures (confirmed by scanning electron microscope)
were separated from small lyophilisomes. These results were
substantiated by qNano size analysis using a lyophilisome
preparation before (Fig. 3a) and after (Fig. 3b) sorting (approxi-
mately 90% below 1 mm). Measurements using the qNano
consisted of 200–250 particles. The size distribution contained
multiple peaks that can be explained by the low number of
particles. Due to the limitations of the qNano instrument particles
smaller than 600 nm could not be reliably detected which
overestimates the average size of the lyophilisomes. Pilot
experiments with a smaller qNano pore (200–800 nm) revealed
the presence of lyophilisomes below 600 nm (results not shown),
but larger lyophilisomes in the preparation frequently blocked this
pore.
Cellular uptake of TAT-conjugated lyophilisomes
Trypan blue assay and FACS. To determine the internal-
ization efficiency of sorted lyophilisomes with and without TAT
peptide, a trypan blue quenching assay was used in order to
distinguish between internalized and non-internalized (but plasma
membrane-associated) lyophilisomes. This assay is based on the
quenching of fluorescence of FITC-labeled lyophilisomes by the
vital stain trypan blue (which does not penetrate plasma
membranes). To validate that trypan blue also quenches
fluorescence of FITC labeled lyophilisomes, lyophilisomes were
incubated with trypan blue in the absence of cells and evaluated by
FACS (Fig. 4). Lyophilisomes that were not incubated with trypan
blue showed a mean fluorescence intensity of 13396252.
Lyophilisomes incubated in a 0.5% trypan blue solution gave a
mean fluorescent intensity of 85631, corresponding to a
quenching efficacy of 9462% (Fig. 4b). After one, two and three
washings after the trypan blue incubation, the measured mean
fluorescence was 161625, 176622, and 192619 or 8861%,
8761% and 8561% quenching efficacy, respectively. This
indicates that trypan blue was not easily washed out of the
lyophilisomes and fluorescence remained quenched. This is
important as three washings steps were used prior to FACS
analysis.
To investigate whether TAT peptides can enhance internaliza-
tion of sorted lyophilisomes, the trypan blue quenching assay was
performed in the presence of HeLa cells (Fig. 5). Cells were
incubated with 500,000 sorted lyophilisomes with and without
TAT peptide. Incubation for 1 h with TAT-conjugated lyophili-
Figure 2. Cellular binding and internalization of unmodified
lyophilisomes and TAT-conjugated lyophilisomes. HeLa, OVCAR-
3, Caco-2 and SKOV-3 cells incubated with TAT-conjugated and
unmodified lyophilisomes resulted in 8663% and 1264%, 8763%
and 1668%, 9763% and 1963%, and 95610% and 67620%
lyophilisome-positive cells, respectively. TAT = trans-activating tran-
scriptional activator. *p,0.01 ***p,0.0001.
doi:10.1371/journal.pone.0110813.g002
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somes resulted in many lyophilisome-positive cells (6763%) and
moderate cellular uptake (25%61). In contrast, unmodified
lyophilisomes showed few lyophilisome-positive cells (665%) and
almost no internalization (161%). Interestingly, when lyophili-
somes were incubated for 4 h, the number of lyophilisome-positive
cells of TAT-conjugated lyophilisomes remained high (7968%)
and cellular uptake strongly increased (59614%), whereas
unmodified lyophilisomes still showed a moderate number of
lyophilisome-positive cells (1768%) and little internalization
(762%).
Confocal microscopy. Internalization of TAT-conjugated
lyophilisomes in HeLa cells was visualized by confocal microscopy
(Fig. 6). After 4 h of incubation, TAT-conjugated lyophilisomes
showed extensive uptake for both low (0.8 million/200 ml) and high
(3.5 million/200 ml) numbers of lyophilisomes (Fig. 6c/g). Almost
no internalization was observed when HeLa cells were incubated
with unmodified lyophilisomes (Fig. 6a/e). The corresponding
bright field images showed that lyophilisomes did not lead to
detectable morphological changes of the cells (Fig. 6b/d/f/h).
Transmission electron microscopy. In order to investigate
the binding and uptake of TAT-conjugated lyophilisomes in HeLa
cells in detail, TEM was used (Fig. 7). When unmodified
lyophilisomes were added to HeLa cells, no binding or uptake
was observed and the plasma membrane appeared largely
unruffled (Fig. 7a). However, when TAT-conjugated lyophili-
somes were added, multiple stages of internalization could be
distinguished, including attachment and internalization (Fig. 7b/
c). Initially, TAT-conjugated lyophilisomes bound to HeLa cells
and initiated membrane ruffling (Fig. 7b). Subsequently, capsules
were internalized (Fig. 7c). Furthermore, initial signs of degrada-
tion of lyophilisomes could be observed, as degradation products
were visible (black arrows; Fig. 7d).
Figure 3. Sorting of lyophilisomes by fluorescence-activated cell sorting. a/b) A representative size distribution of the initial lyophilisome
population (a) and sorted lyophilisomes (b) is depicted, showing smaller lyophilisomes after sorting. Note the difference in x and y axes. c) Initial
lyophilisome population depicted in a FACS dot plot with forward (size)/FITC-positive lyophilisome (FL1 channel) scatter where gated FITC-positive
lyophilisomes were sorted. d) After sorting, the scatter showed merely small lyophilisomes, as large lyophilisomes were removed.
doi:10.1371/journal.pone.0110813.g003
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Discussion
Our laboratory previously demonstrated that lyophilisomes
show potential as a drug delivery system [11,12]. To further
optimize these biocapsules, we studied the effect of TAT-
functionalization on the in vitro internalization of lyophilisomes.
Intracellular delivery of therapeutic molecules is one of the key
problems in drug delivery. Many pharmaceutical compounds have
to be delivered intracellularly to exert their therapeutic action
[22]. CPPs have been shown to act as a powerful transport vector
for inducing the cellular uptake of a large variety of cargos [18]. At
present, pharmaceutical nanocarriers are much in focus for their
capacity to increase the stability of administered drugs, improve
their concentration at their site-of-action and decrease undesired
side effects. Various studies report increased uptake and specific
delivery to intracellular organelles when conjugating CPPs to drug
delivery systems, thereby increasing the efficiency of nanocarriers
as drug delivery systems [35–37].
As previously reported, lyophilisomes range in size from 100 up
to 3,000 nm in diameter [11]. In this study, we demonstrated that
using FACS, small lyophilisomes could be sorted out of the initial
population, narrowing the size distribution.
In the present study, FACS was used to investigate the total cell
binding and internalization of (TAT-conjugated) lyophilisomes in
HeLa, OVCAR-3, Caco-2, and SKOV-3 cells. To investigate the
cellular uptake and subcellular distribution of (TAT-conjugated)
lyophilisomes in HeLa cells in more detail, confocal microscopy,
and TEM were utilized. FACS demonstrated a high number of
lyophilisome-positive cells when incubated with TAT-conjugated
lyophilisomes compared to unmodified lyophilisomes. This may be
explained by interaction of the TAT peptide with negatively
charged sulfated glycans at the cell surface, such as heparan
sulphate [38,39]. Only SKOV-3 cells showed a high background
when incubated with unmodified lyophilisomes, which has been
shown for other drug carriers added to this cell line [40].
To discriminate between internalization and attachment, a
trypan blue quenching assay was applied on HeLa cells incubated
with lyophilisomes. This assay showed that cellular uptake was
enhanced when TAT peptides were conjugated to lyophilisomes.
The degree of internalization may even have been underestimated
as our capsules are likely to enter the acidic lysosomes in the cell
[41] and since FITC fluorescein is virtually non-fluorescent below
Figure 4. Quenching of FITC fluorescent lyophilisomes by trypan blue in the absence of cells. Results show decreased fluorescence (a)
and efficient quenching (b) up to three washings steps of FITC fluorescent lyophilisomes by trypan blue.
doi:10.1371/journal.pone.0110813.g004
Figure 5. Internalization of lyophilisomes with and without
TAT peptide into HeLa cells. FACS showed a large number of
lyophilisome-positive cells for TAT-conjugated lyophilisomes after 1 h
(6763%) without trypan blue and a cellular uptake of 2561% with
trypan blue. Values for lyophilisomes without TAT peptide were low.
When lyophilisomes were incubated for 4 h, TAT-conjugated lyophili-
somes conserved the large number of lyophilisome-positive cells
(7968%) with an increased internalization of 59614%, while unmod-
ified lyophilisomes still showed few lyophilisome-positive cells and little
cellular uptake. *p,0.01 **p,0.001. CPP = cell penetrating peptide;
TAT = trans-activating transcriptional activator.
doi:10.1371/journal.pone.0110813.g005
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pH 5 [42]. The trypan blue assay also demonstrated that cellular
uptake of TAT-conjugated lyophilisomes increased over time.
After 1 h, 2561% of the cells internalized TAT-conjugated
lyophilisomes, whereas 59614% of cells had done so after an
incubation period of 4 h. We most likely added too little
lyophilisomes in the trypan blue internalization study to achieve
lyophilisome internalization of all available cells. This is supported
by confocal microscopy, which revealed that almost all cells
internalized at least one lyophilisome when administering more
lyophilisomes. TEM images showed different stages of cellular
uptake (attachment and internalization) of TAT-conjugated
lyophilisomes. The results strongly suggest that TAT-conjugated
lyophilisomes are internalized by phagocytosis and/or macro-
pinocytosis, as intensive plasma membrane ruffling was observed
during uptake. This suggestion would be in line with the particle
size of lyophilisomes [43]. However, lyophilisomes smaller than
200 nm, could still be internalized by one of the mechanisms of
endocytosis.
Figure 6. Internalization of lyophilisomes without and with
TAT peptide by HeLa cells. Lyophilisomes without and with TAT
peptide were administered to 30,000 HeLa cells using two dosages (0.8
million/500 ml (a-d) and 3.5 million/500 ml (e-h). Cells incubated with
lyophilisomes without TAT peptide had internalized few lyophilisomes
(a/e), whereas TAT-conjugated lyophilisomes showed high cellular
uptake for almost all cells (c/g). Green fluorescence corresponds to
lyophilisomes and red fluorescence (CellMask orange) visualizes the
plasma membrane. Bright field images (b/d/f/h) show normal
morphology of the cells. Scale bar represents 20 mm. TAT = trans-
activating transcriptional activator.
doi:10.1371/journal.pone.0110813.g006
Figure 7. Cellular uptake of TAT-conjugated lyophilisomes as
analyzed by transmission electron microscopy. HeLa cells were
incubated with unmodified (a) and TAT-conjugated lyophilisomes (b-d)
for 4 h. a) No attachment or uptake was observed using unmodified
lyophilisomes. b-d) TAT-conjugated lyophilisomes (white arrows)
showed various processes required for effective drug delivery systems,
such as attachment (b) and uptake (c). Additionally, signs of
degradation of the capsule inside the cell were visualized (black
arrows, d). Scale bar represents 1.0 mm. TAT = trans-activating
transcriptional activator.
doi:10.1371/journal.pone.0110813.g007
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If we compare our findings to other studies, the increased
internalization efficiency compared to unmodified particles is
within the range of reported values for TAT peptides conjugated
to cargos such as liposomes [44,45]. However, it is difficult to
compare internalization for different kinds of nanoparticles, since
different cell types and different amounts and sizes of nanoparticles
are used for in vitro experiments, e.g. the larger the particle the
more time it takes to establish internalization [46].
The ability of CPPs to enhance cellular uptake non-specifically
and receptor-independently provides the opportunity to target
diverse cell types with a variety of carriers. In literature, it has been
observed that next to HeLa, OVCAR-3, Caco-2 and SKOV-3
cells, the TAT peptide can enter other tumor cells, for instance
bladder cancer (HTB-9, MBT2), breast cancer (SK-BR-3, MCF7),
and other colon cancer (C26) cells [45,47]. However, their non-
specificity presents a significant challenge in systemically admin-
istered applications for targeted delivery, as it requires precise
control of CPP presentation only at the target site to prevent
toxicity [48]. To overcome this problem, several approaches are
being investigated to activate CPPs only at the target site.
Stimulus-responsive materials may be used for this purpose, as
they may provide triggered changes in material properties that
allow spatially focused presentation of CPPs in response to
intrinsic disease characteristics (e.g. abundantly present extracel-
lular matrix proteases) or locally applied extrinsic cues (e.g. apply
heat or light at a specific location) [49].
As demonstrated in this study, TAT peptides can enhance
cellular uptake when conjugated to lyophilisomes. In previous in
vitro studies, lyophilisomes were loaded with anti-tumor drugs, e.g.
doxorubicin and curcumin, which could eliminate tumor cells.
Antibodies were conjugated to lyophilisomes resulting in specific
binding to target cells [11,12]. To probe the possibility of using
lyophilisomes for the treatment of cancer, active targeting with
specific antibodies and enhanced cellular uptake with CPPs can be
combined with the drug delivery properties of lyophilisomes,
thereby creating a potential powerful tool for drug delivery.
Conclusion
In the present study, albumin-based lyophilisomes were
functionalized with TAT peptides to obtain a drug delivery
system with enhanced cellular uptake. Lyophilisomes modified
with TAT peptides efficiently bound to HeLa, OVCAR-3, Caco-2
and SKOV-3 cells. Additional cellular uptake studies were
performed to verify that TAT-conjugated lyophilisomes were
internalized in HeLa cells after binding. TAT-conjugated lyophili-
somes may present a novel delivery system to ensure faster and
higher cellular uptake of anti-tumor drugs to cancer cells.
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